Myo-Inositol

Based on the available evidence, myo-inositol appears to have several clinical applications, though the evidence base is limited in the provided materials.

Reproductive Health and Fertility
One completed clinical trial (NCT03055442) investigated the myo-inositol/D-chiro-inositol ratio in follicular fluid, suggesting potential applications in fertility treatments. This aligns with established research indicating inositol compounds may help with ovarian function and egg quality, though specific outcomes from this study are not detailed in the available evidence.

Dermatological Applications
A clinical trial (NCT05855629) evaluated D-chiro-inositol in combination with other treatments for mild to moderate acne vulgaris. The study compared various interventions including topical adapalene, benzoyl peroxide, oral Lactobacillus rhamnosus, and D-chiro-inositol, though the specific results and efficacy data are not provided in the available materials.

Bone Health
Currently recruiting research (NCT07256769) is examining the combination of vitamin K, D-chiro-inositol, and α-lactalbumin for bone homeostasis, indicating potential applications in skeletal health, though outcomes are pending.

Other Potential Applications
Additional trials suggest broader therapeutic exploration, including:

• Urinary tract health (NCT04860492 involving a dietary supplement)
• Topical applications for breast pain (NCT07257770)

Evidence Limitations
The current evidence base is thin, with most clinical trials either completed without published results or still recruiting participants. The available PubMed findings focus on plant biology, marine organisms, and other research areas that do not directly inform myo-inositol's clinical applications. More robust clinical trial data and published outcomes are needed to establish definitive therapeutic benefits.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before starting any new supplement regimen.